ストックスクリーナーアプリを入手
3.82
2.19%
-0.07
前日終値:
$3.89
開ける：
$3.69
24時間の取引高:
226.96K
Relative Volume:
0.33
時価総額：
$231.89M
収益：
-
当期純損益:
$-130.41M
株価収益率:
-1.7054
EPS:
-2.24
ネットキャッシュフロー:
$-67.76M
1週間 パフォーマンス:
-25.39%
1か月 パフォーマンス:
-34.96%
6か月 パフォーマンス:
-25.25%
1年 パフォーマンス:
-45.87%
1日の値動き範囲:
$3.65
$3.89
1週間の範囲:
$3.65
$4.955
52週間の値動き範囲:
$3.21
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
名前
Monte Rosa Therapeutics Inc
セクター
電話
617-949-2643
住所
321 HARRISON AVENUE, BOSTON
GLUE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
3.805 | 231.89M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.87 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
592.12 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.80 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
248.65 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
243.75 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 開始されました | UBS | Buy |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
すべてを表示
Monte Rosa Therapeutics Inc (GLUE) 最新ニュース
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Holdings Boosted by Charles Schwab Investment Management Inc. - Defense World
Chandra Leo Spends US$58k On Monte Rosa Therapeutics Stock - simplywall.st
Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock - Investing.com Australia
Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Position Lifted by Bank of New York Mellon Corp - Defense World
Monte Rosa Therapeutics: Exercise Extreme Caution (NASDAQ:GLUE) - Seeking Alpha
FY2029 Earnings Estimate for GLUE Issued By Wedbush - Defense World
Wells Fargo & Company Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript - Insider Monkey
Wedbush Reaffirms Outperform Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Promising Clinical Developments and Strategic Partnerships Drive Buy Rating for Monte Rosa Therapeutics - TipRanks
Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN
Monte Rosa Therapeutics Earnings Call Highlights Progress and Strategic Shifts - TipRanks
Positive signs for Monte Rosa in early data - The Pharma Letter
Monte Rosa Therapeutics Reports Strong Q4 2024 Results - TipRanks
Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs - TipRanks
Monte Rosa Therapeutics shares surge on strong Q4 revenue beat - Investing.com
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Benzinga
Monte Rosa Therapeutics earnings missed by $0.54, revenue topped estimates - Investing.com Canada
Monte Rosa Therapeutics shares surge on strong Q4 revenue beat By Investing.com - Investing.com Australia
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Monte Rosa Therapeutics Files $400 Million Mixed Shelf -March 20, 2025 at 10:11 am EDT - MarketScreener
Earnings call transcript: Monte Rosa Therapeutics Q4 2024 shows strong cash runway - Investing.com
MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq
Monte Rosa Therapeutics sees cash runway into 2028 - TipRanks
Monte Rosa Therapeutics, Inc. SEC 10-K Report - TradingView
Monte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9M - TipRanks
Updated: Monte Rosa reports first data for molecular glue program licensed to Novartis - Endpoints News
Monte Rosa Therapeutics Reports Q4 2024 Financial Results - TipRanks
Monte Rosa Therapeutics Announces Fourth Quarter 2024 - GlobeNewswire
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - The Manila Times
Monte Rosa's Breakthrough: 90% Target Degradation Success Powers $60M Quarter - StockTitan
Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight - Lelezard
When (GLUE) Moves Investors should Listen - news.stocktradersdaily.com
Lexeo Therapeutics (NASDAQ:LXEO) & Monte Rosa Therapeutics (NASDAQ:GLUE) Critical Survey - Defense World
What is Lifesci Capital’s Forecast for GLUE FY2024 Earnings? - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) Coverage Initiated at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform Recommendation - Nasdaq
Monte Rosa Therapeutics to Present Pipeline Update and - GlobeNewswire
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - The Manila Times
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year ... - The Bakersfield Californian
Monte Rosa Reveals Critical Clinical Data from Two Cancer Drug Trials Plus 2024 Earnings - StockTitan
Rhumbline Advisers Acquires 9,323 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Monte Rosa Therapeutics (GLUE) Projected to Post Earnings on Thursday - Defense World
Monte Rosa Therapeutics Inc (GLUE) 財務データ
収益
当期純利益
現金流量
EPS
2.65%
0.06%
大文字化:
|
ボリューム (24 時間):